1. Home
  2. companies
  3. Lantus

Lantus

The top 10 patent losses of 2015
The top 10 patent losses of 2015
Fierce Pharma
patents
Lantus
Abilify
Copaxone
Neulasta
Tracleer
Namenda
Avodart
Jalyn
Zyvox
Androgel
Synagis
Sanofi
Bristol-Myers Squibb
Otsuka
Teva Pharmaceutical
Amgen
Actelion
Actavis
GSK
Pfizer
AbbVie
AstraZeneca
Digesting Sanofi's Two Pieces Of News- Lantus' Challenging Outlook And The CEO Dismissal
Digesting Sanofi's Two Pieces Of News- Lantus' Challenging Outlook And The CEO Dismissal
Seeking Alpha
Sanofi
Lantus
Chris Viehbacher
Sanofi shares plunge after diabetes drug warning
Sanofi shares plunge after diabetes drug warning
Yahoo/AP
Sanofi
diabetes
Lantus
Sanofi And Novo Nordisk‘s Basal-Insulin Battle Continues
Sanofi And Novo Nordisk‘s Basal-Insulin Battle Continues
Bidness Etc.
Sanofi
Novo Nordisk
basal insulin
diabetes
Lantus
Levemir
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Bidness Etc.
Sanofi
Novo Nordisk
diabetes
insulin
Lantus
Tresiba
Toujeo
Who's Winning The Insulin Showdown?
Who's Winning The Insulin Showdown?
Bidness Etc.
insulin
diabetes
Eli Lilly
Sanofi
Lantus
Peglispro
Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown
Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown
Fierce Biotech
Eli Lilly
Sanofi
Lantus
diabetes
basal insulin peglispro
Sanofi sues Eli Lilly over insulin rival to Lantus
Sanofi sues Eli Lilly over insulin rival to Lantus
Yahoo/Reuters
Sanofi
Eli Lilly
Lantus
diabetes
insulin
Lilly Wins EU Backing for Generic of Sanofi’s Lantus
Lilly Wins EU Backing for Generic of Sanofi’s Lantus
Bloomberg
Europe
generics
Eli Lilly
Sanofi
Lantus
diabetes
New rivals to top diabetes drug Lantus show promise in studies
New rivals to top diabetes drug Lantus show promise in studies
Yahoo/Reuters
diabetes
Lantus
insulin
Sanofi
Toujeo
Eli Lilly
Lilly's diabetes drug as effective as Sanofi's in late-stage trials
Lilly's diabetes drug as effective as Sanofi's in late-stage trials
Yahoo/Reuters
Eli Lilly
Sanofi
diabetes
basal insulin peglispro
Lantus
10 big brands keep pumping out big bucks, with a little help from price hikes
10 big brands keep pumping out big bucks, with a little help from price hikes
Fierce Pharma Marketing
Xyrem
Jazz Pharmaceuticals
Humulin
Eli Lilly
Premarin
Mylan
Lunesta
Sunovion
Benicar
Daiichi Sankyo
Lantus
Sanofi
Viagra
Pfizer
Gleevec
Novartis
Copaxone
Teva Pharmaceuticals
EpiPen
drug pricing
The 10 best-selling drugs of 2013
The 10 best-selling drugs of 2013
Fierce Pharma
Seretide
Rituxan
Remicade
MabThera
Lantus
Humira
Herceptin
Enbrel
Crestor
Avastin
Advair
Abilify
Novo Nordisk sees chance of U.S. Tresiba launch before rival products
Novo Nordisk sees chance of U.S. Tresiba launch before rival products
Yahoo/Reuters
Novo Nordisk
insulin
diabetes
Tresiba
Lantus
Sanofi
Eli Lilly
Merck joins race to copy Sanofi's diabetes drug Lantus
Merck joins race to copy Sanofi's diabetes drug Lantus
Yahoo/Reuters
Lantus
diabetes
Sanofi
Merck
Sanofi sues Eli Lilly over patents for top-selling insulin drug
Sanofi sues Eli Lilly over patents for top-selling insulin drug
Yahoo/Reuters
Sanofi
Eli Lilly
insulin
diabetes
Lantus
Sanofi's LixiLan Progresses
Sanofi's LixiLan Progresses
Yahoo/Zacks.com
Sanofi
LixiLan
insulin
Lantus
diabetes
Zealand Pharma
Lyxumia
U.S. Insulin Prices Rise as Sanofi, Novo Await Rivals
U.S. Insulin Prices Rise as Sanofi, Novo Await Rivals
Bloomberg
insulin
diabetes
Sanofi
Novo Nordisk
Levemir
Lantus
Victoza
The 5 Best-Selling Medications of 2013 (So Far)
The 5 Best-Selling Medications of 2013 (So Far)
Motley Fool
AbbVie
Humira
Advair
GSK
Seretide
Enbrel
Amgen
Pfizer
Lantus
Sanofi
Avastin
Roche
The Future of Sanofi's Insulin Empire
The Future of Sanofi's Insulin Empire
Motley Fool
Sanofi
insulin
Eli Lilly
Novo Nordisk
diabetes
U300
Lantus
LixiLan

Click here to subscribe to daily news headlines in your email inbox